Navigation Links
Colon cancer researchers target stem cells, discover viable new therapeutic path
Date:12/1/2013

(TORONTO, Canada Dec. 1, 2013) - Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.

"This is the first step toward clinically applying the principles of cancer stem cell biology to control cancer growth and advance the development of durable cures," says principal investigator Dr. John Dick about the findings published online today in Nature Medicine.

He talks about the research in this video - click the link to watch: https://www.youtube.com/watch?v=QK7JquljkBc.

Dr. Dick pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007). He is also renowned for isolating a human blood stem cell in its purest form as a single stem cell capable of regenerating the entire blood system paving the way for clinical use (2011). Dr. Dick holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's Princess Margaret Cancer Centre and McEwen Centre for Regenerative Medicine. He is also a Professor in the Department of Molecular Genetics, University of Toronto, and Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research.

In pre-clinical experiments, the research team replicated human colon cancer in mice to determine if specifically targeting the stem cells was clinically relevant. First, the researchers identified that the gene BMI-1, already implicated in maintaining stem cells in other cancers, is the pivotal regulator of colon cancer stem cells and drives the cycle of self-renewal, proliferation and cell survival. Next, the team used an existing small-molecule inhibitor to successfully block BMI-1, thus demonstrating the clinical relevance of this approach.

Lead author Dr. Antonija Kreso writes: "Inhibiting a recognized regulator of self-renewal is an effective approach to control tumor growth, providing strong evidence for the clinical relevance of self-renewal as a biological process for therapeutic targeting."

Dr. Dick explains: "When we blocked the BMI-1 pathway, the stem cells were unable to self-renew, which resulted in long-term and irreversible impairment of tumour growth. In other words, the cancer was permanently shut down."

Surgeon-scientist Dr. Catherine O'Brien, senior co-author of the study says: "The clinical potential of this research is exciting because it maps a viable way to develop targeted treatment for colon cancer patients. It is already known that about 65% have the BMI-1 biomarker. With the target identified, and a proven way to tackle it, this knowledge could readily translate into first-in-human trials to provide more personalized cancer medicine."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert  

Related biology news :

1. Hardworking sisters enable insect colonies to thrive
2. Colon cancer screening guidelines may miss 10 percent of colon cancers
3. Research shows how aspirin may act on blood platelets to improve survival in colon cancer patients
4. Scientists learn how soy foods protect against colon cancer
5. New 3-D colonoscopy eases detection of precancerous lesions
6. Scientists discover thriving colonies of microbes in ocean plastisphere
7. University of Tennessee professor links massive prehistoric bird extinction to human colonization
8. Researchers id queens, mysterious disease syndrome as key factors in bee colony deaths
9. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
10. Two-faced cells discovered in colon cancer
11. E. coli adapts to colonize plants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Colon cancer researchers target stem cells, discover viable new therapeutic path
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... June 28, 2017 , ... Ovation Fertility continues ... for presentation at the 33rd Annual Meeting of the European Society of ... the world’s top thought leaders in reproductive medicine – are expected to attend ...
(Date:6/28/2017)... ... June 28, 2017 , ... Supplies of the critical medical isotope molybdenum-99 ... the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, ... used in 30 to 40 million nuclear medicine procedures worldwide every year. (1) ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, ... Kickstarter campaign on June 15th to fund production of the new B2v2 wearable ... original Kickstarter goal by more than 150% in a little over a week. ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based ... GX-1 yeast production and fermentation process. The efficiencies created by the newest ... technologies, most notably the ethanol industry wherein individual production plants are planning to ...
Breaking Biology Technology: